Stock Analiz

Nurix Therapeutics, Inc. (NRIX) earnings: date, estimates and history

Price $15.48 · data as of November 13, 2026

Next earnings report

Next reportNot announced yet
Quarterending November 30, 2026
EPS estimate$1.51
Revenue estimate$288M
Expected EPS growth+283.9%

The date appears here once Nurix Therapeutics confirms it, usually two to four weeks before the report.

Track record

Beat EPS estimates1 of 5
Average surprise−6.5%
Average move on report day±3.8%

Nurix Therapeutics beat the consensus earnings estimate in 1 of its last 5 reports, by −6.5% on average. On report days the stock moved 3.8% on average, up or down.

Earnings history

ReportedEPS estimateEPS actualSurpriseRevenueRevenue growthStock move
October 12, 2026
Aug/2026
$5.02$4.73−5.7%$673M+8426.3%−1.7%
July 9, 2026
May/2026
$-0.72$-0.81−13.1%$9M−79.5%−5.1%
April 8, 2026
Feb/2026
$-0.76$-0.79−3.3%$6M−66.1%−0.7%
January 28, 2026
Nov/2025
$-0.92$-0.82+10.8%$14M+2.2%−9.4%
October 9, 2025
Aug/2025
$-0.85$-1.03−21.1%$8M−37.3%−2.2%

EPS as compared with analyst estimates (adjusted EPS). Revenue growth is against the same quarter a year earlier. Stock move: change on the first trading day after the report.

Frequently asked questions

When is Nurix Therapeutics’s next earnings date?

Nurix Therapeutics has not confirmed its next report date yet. Its last report was on October 12, 2026.

Did Nurix Therapeutics beat earnings last quarter?

No, it reported EPS of $4.73 on October 12, 2026 against an estimate of $5.02 (a −5.7% surprise), and the stock moved −1.7% the next trading day.

What EPS do analysts expect next quarter?

The consensus estimate is $1.51 per share on revenue of about $288M.

Report dates and estimates from analyst consensus data; results from company reports. Updated daily. Not investment advice. Earnings calendar